New Zealand markets closed

Cullinan Therapeutics, Inc. (CGEM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.43-0.08 (-0.46%)
At close: 04:00PM EDT
17.43 0.00 (0.00%)
After hours: 04:57PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.00B
Enterprise value 574.72M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.36
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.06
52-week change 353.23%
S&P500 52-week change 326.24%
52-week high 330.19
52-week low 37.64
50-day moving average 322.40
200-day moving average 314.69

Share statistics

Avg vol (3-month) 3904.52k
Avg vol (10-day) 31.25M
Shares outstanding 557.63M
Implied shares outstanding 657.63M
Float 837.56M
% held by insiders 14.54%
% held by institutions 178.79%
Shares short (15 May 2024) 43.74M
Short ratio (15 May 2024) 42.85
Short % of float (15 May 2024) 47.54%
Short % of shares outstanding (15 May 2024) 46.49%
Shares short (prior month 15 Apr 2024) 41.68M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-22.15%
Return on equity (ttm)-29.47%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -170.57M
Net income avi to common (ttm)-132.35M
Diluted EPS (ttm)-3.13
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)433.01M
Total cash per share (mrq)7.51
Total debt (mrq)3.17M
Total debt/equity (mrq)0.74%
Current ratio (mrq)20.33
Book value per share (mrq)9.88

Cash flow statement

Operating cash flow (ttm)-121.53M
Levered free cash flow (ttm)-81.68M